Valeant completes purchase of Bausch & Lomb Valeant Pharmaceuticals (VRX) completes the $8.7B acquisition of Bausch & Lomb. Valeant expects savings of over $800M from the deal, including more than $500M this year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.